The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
[EN] FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS<br/>[FR] PIPÉRIDINES CONDENSÉES UTILISÉES COMME AGONISTES DU RÉCEPTEUR IP POUR LE TRAITEMENT DE L'HYPERTENSION ARTÉRIELLE PULMONAIRE (HTAP) ET DE TROUBLES ASSOCIÉS
申请人:NOVARTIS AG
公开号:WO2013105063A1
公开(公告)日:2013-07-18
The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Formula (I):
[EN] IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES AGONISTES DU RÉCEPTEUR IP
申请人:NOVARTIS AG
公开号:WO2014125413A1
公开(公告)日:2014-08-21
The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
[EN] FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS<br/>[FR] PIPÉRIDINES CONDENSÉES UTILISÉES COMME AGONISTES DU RÉCEPTEUR IP POUR LE TRAITEMENT DE L'HTAP ET DE TROUBLES CONNEXES
申请人:NOVARTIS AG
公开号:WO2013105065A1
公开(公告)日:2013-07-18
The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.